1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole has been researched along with Sclerosis, Systemic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, CY; Chen, CH; Hsu, WL; Lu, JH; Tsai, MH; Wu, CY; Yen, CJ; Yoshioka, T; Yu, HS | 1 |
1 other study(ies) available for 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole and Sclerosis, Systemic
| Article | Year |
|---|---|
A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca2+ entry.
Topics: Boron Compounds; Calcium Channel Blockers; Calcium Signaling; Cell Dedifferentiation; Cells, Cultured; Cellular Microenvironment; Collagen; Cytoskeleton; Fibroblasts; Humans; Imidazoles; Indomethacin; Scleroderma, Systemic; Skin; Transforming Growth Factor beta1 | 2019 |